EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Modulating the Gut Microbiome as a Therapeutic Approach in Multiple Sclerosis: Implications for Gut‐Brain Interactions and Immune Pathways: A Narrative Review

Husna Irfan Thalib iD, Nuha Fatima iD, Faaleha Heba Fakruddin iD, Hosna Hamidullah Ali iD, Sariya Khan iD, Mohammed Talha Mohammed Zubair iD, Mable Pereira iD, Fatma E Sayed Hassan iD

Brain and Behavior · 2026-02 · 16 (2)

DOI: 10.1002/brb3.71254 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain and Behavior, online erschienen am 05.02.2026. Verfasst von Husna Irfan Thalib und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Medicine Practice Program, Batterjee Medical College, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Multiple Sclerosis, Gastrointestinal Microbiome, Dysbiosis, Brain-Gut Axis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by progressive disability. Emerging evidence has implicated gut microbiome dysbiosis, characterized by decreased short‐chain fatty acids (SCFAs)‐producing taxa and increased pro‐inflammatory species, in disturbed immune signaling, T‐helper17/T‐regulatory cells imbalance, disturbed tryptophan metabolism, and disrupted integrity of the blood–brain barrier. In this review, we summarize the mechanistic and therapeutic insights from studies that have explored the gut microbiome in MS.

Method

We performed a literature search in PubMed, Scopus, Web of Science, and ClinicalTrials.gov from database inception to January 2025; only English‐language articles were included, comprising human MS cohorts and preclinical experimental autoimmune encephalomyelitis models. Of these, approximately 95 human and preclinical studies fulfilled the inclusion criteria. Evidence synthesis was narrative, without meta‐analysis. Finding There has been a consistent depletion of beneficial genera such as Faecalibacterium and Roseburia, expansion of Akkermansia muciniphila, and reduction in microbial metabolites such as butyrate, propionate, and neuroactive indole derivatives in MS patients across studies. These changes promote intestinal permeability, exaggerated pro‐inflammatory cytokine responses, and microglial activation. The therapeutic approach of restoring microbial balance includes therapies such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and dietary interventions. Early trials have shown modest improvements in relapse rates, fatigue, immune profiles, and microbiome composition. Results across randomized studies are heterogeneous, with no significant clinical benefit in several. Pilot trials report modest reductions in relapse rate (RR ≈ 0.85) and fatigue (Cohen's d ≈ 0.3), but several double‑blind RCTs showed no significant benefit ( p > 0.05) in up to 40% of participants, highlighting variable effect sizes.

Conclusion

Interventions aimed at the microbiome are promising as adjunct approaches to the treatment of MS, acting principally through the restoration of SCFAs, immune modulation, and strengthening of the gut‐brain axis. Larger, longer‐term randomized trials are required to confirm clinical efficacy, define responder phenotypes, and inform personalized microbiome‐based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisGastrointestinal MicrobiomeDysbiosisBrain-Gut AxisHumansAnimalsProbioticsBrain

Stichwörter der Autor:innen

fecal microbiota transplantationgut microbiomemultiple sclerosisneuroinflammationprobiotics

Autor:innen und Institutionen

  • General Medicine Practice Program, Batterjee Medical College, Jeddah, Saudi Arabia.
  • School of Medicine, Lincoln American University, Georgetown, Guyana.
  • Medical Physiology Department, Kasr Alainy, Faculty of Medicine, Cairo University, Giza, Egypt.
  • Department of Physiology, General Medicine Practice Program, Batterjee Medical College, Jeddah, Saudi Arabia.

ORCID-Profile: Husna Irfan Thalib, Nuha Fatima, Faaleha Heba Fakruddin, Hosna Hamidullah Ali, Sariya Khan, Mohammed Talha Mohammed Zubair, Mable Pereira, Fatma E Sayed Hassan

Zitieren

APA

Thalib, H. I., Fatima, N., Fakruddin, F. H., Ali, H. H., Khan, S., Zubair, M. T. M., Pereira, M., & Sayed Hassan, F. E. (2026). Modulating the Gut Microbiome as a Therapeutic Approach in Multiple Sclerosis: Implications for Gut‐Brain Interactions and Immune Pathways: A Narrative Review. Brain and Behavior, 16(2). https://doi.org/10.1002/brb3.71254

Vancouver

Thalib HI, Fatima N, Fakruddin FH, Ali HH, Khan S, Zubair MTM, et al. Modulating the Gut Microbiome as a Therapeutic Approach in Multiple Sclerosis: Implications for Gut‐Brain Interactions and Immune Pathways: A Narrative Review. Brain and Behavior. 2026;16(2). doi:10.1002/brb3.71254

BibTeX
@article{Thalib2026,
  author = {Thalib, Husna Irfan and Fatima, Nuha and Fakruddin, Faaleha Heba and Ali, Hosna Hamidullah and Khan, Sariya and Zubair, Mohammed Talha Mohammed and Pereira, Mable and Sayed Hassan, Fatma E},
  title = {Modulating the Gut Microbiome as a Therapeutic Approach in Multiple Sclerosis: Implications for Gut‐Brain Interactions and Immune Pathways: A Narrative Review},
  journal = {Brain and Behavior},
  year = {2026},
  volume = {16},
  number = {2},
  doi = {10.1002/brb3.71254}
}
Kostenlos starten →